Tr
Trillium (Pfizer)
Toronto CAFounded 200450 employees
Private CapbiotechAcquiredOncology
Platform: TTI-622 CD47
Market Cap
N/A
All Drugs
4
Clinical Trials
11
Failed / Terminated
2
FDA Approved
1
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Gozesertib | TRI-8137 | Phase 1/2 | 2 | CDK2 | GAMeso | ||
| TRI-2954 | TRI-2954 | Approved | 4 | FLT3 | DravetT2D | ||
| Olpazasiran | TRI-1061 | Phase 3 | 3 | FcRn | ADHDCholangiocarcinoma | ||
| TRI-2500 | TRI-2500 | Phase 1/2 | 2 | AHR | WilmsCeliac |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (8)